Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer’s Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials

Author(s): Ping-Tao Tseng, Bing-Yan Zeng, Yen-Wen Chen, Chun-Pai Yang, Kuan-Pin Su, Tien-Yu Chen, Yi-Cheng Wu, Yu-Kang Tu, Pao-Yen Lin, Andre F. Carvalho, Brendon Stubbs, Yutaka J. Matsuoka, Dian-Jeng Li, Chih-Sung Liang, Chih-Wei Hsu, Cheuk-Kwan Sun, Yu-Shian Cheng, Pin-Yang Yeh and Yow-Ling Shiue*

Volume 20, Issue 10, 2022

Published on: 08 June, 2022

Page: [1816 - 1833] Pages: 18

DOI: 10.2174/1570159X20666220420122322

Price: $65

Abstract

Background: While Alzheimer’s dementia (AD) has a prevalence as high as 3-32% and is associated with cognitive dysfunction and the risk of institutionalization, no efficacious and acceptable treatments can modify the course of cognitive decline in AD. Potential benefits of exogenous melatonin for cognition have been divergent across trials.

Objective: The current network meta-analysis (NMA) was conducted under the frequentist model to evaluate the potential beneficial effects of exogenous melatonin supplementation on overall cognitive function in participants with AD in comparison to other FDA-approved medications (donepezil, galantamine, rivastigmine, memantine, and Namzaric).

Methods: The primary outcome was the changes in the cognitive function [measured by mini-mental state examination (MMSE)] after treatment in patients with Alzheimer’s dementia. The secondary outcomes were changes in the quality of life, behavioral disturbance, and acceptability (i.e., drop-out due to any reason and rate of any adverse event reported).

Results: The current NMA of 50 randomized placebo-controlled trials (RCTs) revealed the medium-term lowdose melatonin to be associated with the highest post-treatment MMSE (mean difference = 1.48 in MMSE score, 95% confidence intervals [95% CIs] = 0.51 to 2.46) and quality of life (standardized mean difference = -0.64, 95% CIs = -1.13 to -0.15) among all of the investigated medications in the participants with AD. Finally, all of the investigated exogenous melatonin supplements were associated with similar acceptability as was the placebo.

Conclusion: The current NMA provides evidence for the potential benefits of exogenous melatonin supplementation, especially medium-term low-dose melatonin, in participants with AD.

Keywords: Alzheimer’s dementia, quality of life, cognition, network meta-analysis, dementia, melatonin, circadian rhythm, psychiatry.

« Previous Next »
Graphical Abstract

[1]
Hebert, L.E.; Weuve, J.; Scherr, P.A.; Evans, D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology, 2013, 80(19), 1778-1783.
[http://dx.doi.org/10.1212/WNL.0b013e31828726f5] [PMID: 23390181]
[2]
González-Salvador, T.; Lyketsos, C.G.; Baker, A.; Hovanec, L.; Roques, C.; Brandt, J.; Steele, C. Quality of life in dementia patients in long-term care. Int. J. Geriatr. Psychiatry, 2000, 15(2), 181-189.
[http://dx.doi.org/10.1002/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I] [PMID: 10679850]
[3]
Riemersma-van der Lek, R.F.; Swaab, D.F.; Twisk, J.; Hol, E.M.; Hoogendijk, W.J.; Van Someren, E.J. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: A randomized controlled trial. JAMA, 2008, 299(22), 2642-2655.
[http://dx.doi.org/10.1001/jama.299.22.2642] [PMID: 18544724]
[4]
Donaldson, C.; Tarrier, N.; Burns, A. Determinants of carer stress in Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 1998, 13(4), 248-256.
[http://dx.doi.org/10.1002/(SICI)1099-1166(199804)13:4<248::AID-GPS770>3.0.CO;2-0] [PMID: 9646153]
[5]
Devanand, D.P.; Jacobs, D.M.; Tang, M.X.; Del Castillo-Castaneda, C.; Sano, M.; Marder, K.; Bell, K.; Bylsma, F.W.; Brandt, J.; Albert, M.; Stern, Y. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch. Gen. Psychiatry, 1997, 54(3), 257-263.
[http://dx.doi.org/10.1001/archpsyc.1997.01830150083012] [PMID: 9075466]
[6]
Moore, A.; Patterson, C.; Lee, L.; Vedel, I.; Bergman, H. Fourth Canadian consensus conference on the diagnosis and treatment of dementia: Recommendations for family physicians. Can. Fam. Physician, 2014, 60(5), 433-438.
[PMID: 24829003]
[7]
Valdés-Tovar, M.; Estrada-Reyes, R.; Solís-Chagoyán, H.; Argueta, J.; Dorantes-Barrón, A.M.; Quero-Chávez, D.; Cruz-Garduño, R.; Cercós, M.G.; Trueta, C.; Oikawa-Sala, J.; Dubocovich, M.L.; Benítez-King, G. Circadian modulation of neuroplasticity by melatonin: A target in the treatment of depression. Br. J. Pharmacol., 2018, 175(16), 3200-3208.
[http://dx.doi.org/10.1111/bph.14197] [PMID: 29512136]
[8]
Cardinali, D.P.; Furio, A.M.; Brusco, L.I. Clinical aspects of melatonin intervention in Alzheimer’s disease progression. Curr. Neuropharmacol., 2010, 8(3), 218-227.
[http://dx.doi.org/10.2174/157015910792246209] [PMID: 21358972]
[9]
Cardinali, D.P.; Vigo, D.E.; Olivar, N.; Vidal, M.F.; Brusco, L.I. Melatonin therapy in patients with Alzheimer’s disease. Antioxidants, 2014, 3(2), 245-277.
[http://dx.doi.org/10.3390/antiox3020245] [PMID: 26784870]
[10]
Moe, K.E.; Vitiello, M.V.; Larsen, L.H.; Prinz, P.N. Symposium: Cognitive processes and sleep disturbances: Sleep/wake patterns in Alzheimer’s disease: relationships with cognition and function. J. Sleep Res., 1995, 4(1), 15-20.
[http://dx.doi.org/10.1111/j.1365-2869.1995.tb00145.x] [PMID: 10607136]
[11]
Walker, M.P.; Stickgold, R. Sleep-dependent learning and memory consolidation. Neuron, 2004, 44(1), 121-133.
[http://dx.doi.org/10.1016/j.neuron.2004.08.031] [PMID: 15450165]
[12]
Mishima, K.; Tozawa, T.; Satoh, K.; Matsumoto, Y.; Hishikawa, Y.; Okawa, M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol. Psychiatry, 1999, 45(4), 417-421.
[http://dx.doi.org/10.1016/S0006-3223(97)00510-6] [PMID: 10071710]
[13]
Ohashi, Y.; Okamoto, N.; Uchida, K.; Iyo, M.; Mori, N.; Morita, Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol. Psychiatry, 1999, 45(12), 1646-1652.
[http://dx.doi.org/10.1016/S0006-3223(98)00255-8] [PMID: 10376127]
[14]
Uchida, K.; Okamoto, N.; Ohara, K.; Morita, Y. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res., 1996, 717(1-2), 154-159.
[http://dx.doi.org/10.1016/0006-8993(96)00086-8] [PMID: 8738265]
[15]
Asayama, K.; Yamadera, H.; Ito, T.; Suzuki, H.; Kudo, Y.; Endo, S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J. Nippon Med. Sch., 2003, 70(4), 334-341.
[http://dx.doi.org/10.1272/jnms.70.334] [PMID: 12928714]
[16]
Wade, A.G.; Farmer, M.; Harari, G.; Fund, N.; Laudon, M.; Nir, T.; Frydman-Marom, A.; Zisapel, N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin. Interv. Aging, 2014, 9, 947-961.
[PMID: 24971004]
[17]
Gao, Q.W.; Lio, Y.; Luo, G.Q.; Xiang, W.; Peng, K.R. Effect of melatonin on mild Alzheimer’s disease in elderly male patients. Parct Geriatr, 2009, 23(1), 56-58.
[18]
Singer, C.; Tractenberg, R.E.; Kaye, J.; Schafer, K.; Gamst, A.; Grundman, M.; Thomas, R.; Thal, L.J. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep, 2003, 26(7), 893-901.
[http://dx.doi.org/10.1093/sleep/26.7.893] [PMID: 14655926]
[19]
McCleery, J.; Cohen, D.A.; Sharpley, A.L. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst. Rev., 2014, (3), CD009178.
[PMID: 24659320]
[20]
McCleery, J.; Cohen, D.A.; Sharpley, A.L. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst. Rev., 2016, 11, CD009178.
[PMID: 27851868]
[21]
Wang, Y.Y.; Zheng, W.; Ng, C.H.; Ungvari, G.S.; Wei, W.; Xiang, Y.T. Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2017, 32(1), 50-57.
[http://dx.doi.org/10.1002/gps.4571] [PMID: 27645169]
[22]
Xu, J.; Wang, L.L.; Dammer, E.B.; Li, C.B.; Xu, G.; Chen, S.D.; Wang, G. Melatonin for sleep disorders and cognition in dementia: A meta-analysis of randomized controlled trials. Am. J. Alzheimers Dis. Other Demen., 2015, 30(5), 439-447.
[http://dx.doi.org/10.1177/1533317514568005] [PMID: 25614508]
[23]
McCleery, J.; Sharpley, A.L. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst. Rev., 2020, 11, CD009178.
[PMID: 33189083]
[24]
Sumsuzzman, D.M.; Choi, J.; Jin, Y.; Hong, Y. Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials. Neurosci. Biobehav. Rev., 2021, 127, 459-473.
[http://dx.doi.org/10.1016/j.neubiorev.2021.04.034] [PMID: 33957167]
[25]
Brzezinski, A.; Vangel, M.G.; Wurtman, R.J.; Norrie, G.; Zhdanova, I.; Ben-Shushan, A.; Ford, I. Effects of exogenous melatonin on sleep: A meta-analysis. Sleep Med. Rev., 2005, 9(1), 41-50.
[http://dx.doi.org/10.1016/j.smrv.2004.06.004] [PMID: 15649737]
[26]
Buscemi, N.; Vandermeer, B.; Hooton, N.; Pandya, R.; Tjosvold, L.; Hartling, L.; Vohra, S.; Klassen, T.P.; Baker, G. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ, 2006, 332(7538), 385-393.
[http://dx.doi.org/10.1136/bmj.38731.532766.F6] [PMID: 16473858]
[27]
Sack, R.L.; Hughes, R.J.; Edgar, D.M.; Lewy, A.J. Sleep-promoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms? Sleep, 1997, 20(10), 908-915.
[http://dx.doi.org/10.1093/sleep/20.10.908] [PMID: 9415954]
[28]
Yang, C.P.; Tseng, P.T.; Pei-Chen, C.J.; Su, H.; Satyanarayanan, S.K.; Su, K.P. Melatonergic agents in the prevention of delirium: A network meta-analysis of randomized controlled trials. Sleep Med. Rev., 2020, 50, 101235.
[http://dx.doi.org/10.1016/j.smrv.2019.101235] [PMID: 31801100]
[29]
Higgins, J.P.; Welton, N.J. Network meta-analysis: A norm for comparative effectiveness? Lancet, 2015, 386(9994), 628-630.
[http://dx.doi.org/10.1016/S0140-6736(15)61478-7] [PMID: 26334141]
[30]
Naci, H.; Salcher-Konrad, M.; Kesselheim, A.S.; Wieseler, B.; Rochaix, L.; Redberg, R.F.; Salanti, G.; Jackson, E.; Garner, S.; Stroup, T.S.; Cipriani, A. Generating comparative evidence on new drugs and devices before approval. Lancet, 2020, 395(10228), 986-997.
[http://dx.doi.org/10.1016/S0140-6736(19)33178-2] [PMID: 32199486]
[31]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[32]
Shea, B.J.; Reeves, B.C.; Wells, G.; Thuku, M.; Hamel, C.; Moran, J.; Moher, D.; Tugwell, P.; Welch, V.; Kristjansson, E.; Henry, D.A. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358, j4008.
[http://dx.doi.org/10.1136/bmj.j4008] [PMID: 28935701]
[33]
Urrestarazu, E.; Iriarte, J. Clinical management of sleep disturbances in Alzheimer’s disease: Current and emerging strategies. Nat. Sci. Sleep, 2016, 8, 21-33.
[http://dx.doi.org/10.2147/NSS.S76706] [PMID: 26834500]
[34]
Zhang, W.; Chen, X.Y.; Su, S.W.; Jia, Q.Z.; Ding, T.; Zhu, Z.N.; Zhang, T. Exogenous melatonin for sleep disorders in neurodegenerative diseases: A meta-analysis of randomized clinical trials. Neurol. Sci., 2016, 37(1), 57-65.
[http://dx.doi.org/10.1007/s10072-015-2357-0] [PMID: 26255301]
[35]
Watanabe, M.; Nakamura, Y.; Yoshiyama, Y.; Kagimura, T.; Kawaguchi, H.; Matsuzawa, H.; Tachibana, Y.; Nishimura, K.; Kubota, N.; Kobayashi, M.; Saito, T.; Tamura, K.; Sato, T.; Takahashi, M.; Homma, A. Analyses of natural courses of Japanese patients with Alzheimer’s disease using placebo data from placebo-controlled, randomized clinical trials: Japanese study on the estimation of clinical course of Alzheimer’s disease. Alzheimers Dement. (N. Y.), 2019, 5(1), 398-408.
[http://dx.doi.org/10.1016/j.trci.2019.07.004] [PMID: 31517028]
[36]
Cui, C.C.; Sun, Y.; Wang, X.Y.; Zhang, Y.; Xing, Y. The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis. Medicine (Baltimore), 2019, 98(27), e16091.
[http://dx.doi.org/10.1097/MD.0000000000016091] [PMID: 31277107]
[37]
Glinz, D.; Gloy, V.L.; Monsch, A.U.; Kressig, R.W.; Patel, C.; McCord, K.A.; Ademi, Z.; Tomonaga, Y.; Schwenkglenks, M.; Bucher, H.C.; Raatz, H. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer’s disease: a meta-analysis. Swiss Med. Wkly., 2019, 149, w20093.
[http://dx.doi.org/10.4414/smw.2019.20093] [PMID: 31269225]
[38]
Li, D.D.; Zhang, Y.H.; Zhang, W.; Zhao, P. Meta-Analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front. Neurosci., 2019, 13, 472.
[http://dx.doi.org/10.3389/fnins.2019.00472] [PMID: 31156366]
[39]
Thancharoen, O.; Limwattananon, C.; Waleekhachonloet, O.; Rattanachotphanit, T.; Limwattananon, P.; Limpawattana, P. Ginkgo biloba Extract (EGb761), Cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer’s disease: A network meta-analysis. Drugs Aging, 2019, 36(5), 435-452.
[http://dx.doi.org/10.1007/s40266-019-00648-x] [PMID: 30937879]
[40]
McShane, R.; Westby, M.J.; Roberts, E.; Minakaran, N.; Schneider, L.; Farrimond, L.E.; Maayan, N.; Ware, J.; Debarros, J. Memantine for dementia. Cochrane Database Syst. Rev., 2019, 3, CD003154.
[PMID: 30891742]
[41]
Dou, K.X.; Tan, M.S.; Tan, C.C.; Cao, X.P.; Hou, X.H.; Guo, Q.H.; Tan, L.; Mok, V.; Yu, J.T. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: A network meta-analysis of 41 randomized controlled trials. Alzheimers Res. Ther., 2018, 10(1), 126.
[http://dx.doi.org/10.1186/s13195-018-0457-9] [PMID: 30591071]
[42]
Birks, J.S.; Harvey, R.J. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev., 2018, 6(6), CD001190.
[http://dx.doi.org/10.1002/14651858.CD001190.pub3] [PMID: 29923184]
[43]
Koola, M.M.; Nikiforuk, A.; Pillai, A.; Parsaik, A.K. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: Critical dissection with an emphasis on kynurenic acid and mismatch negativity. J. Geriatr. Care Res., 2018, 5(2), 57-67.
[PMID: 30984874]
[44]
Kishi, T.; Matsunaga, S.; Iwata, N. The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: A meta-analysis. Neuropsychiatr. Dis. Treat., 2017, 13, 1909-1928.
[http://dx.doi.org/10.2147/NDT.S142839] [PMID: 28790827]
[45]
Hsieh, M.T.; Tseng, P.T.; Wu, Y.C.; Tu, Y.K.; Wu, H.C.; Hsu, C.W.; Lei, W.T.; Stubbs, B.; Carvalho, A.F.; Liang, C.S.; Yeh, T.C.; Chen, T.Y.; Chu, C.S.; Li, J.C.; Yu, C.L.; Chen, Y.W.; Li, D.J. Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta-analysis. Obes. Rev., 2019, 20(6), 895-905.
[http://dx.doi.org/10.1111/obr.12835] [PMID: 30816006]
[46]
Tu, Y.K.; Faggion, C.M., Jr A primer on network meta-analysis for dental research. ISRN Dent., 2012, 2012, 276520.
[http://dx.doi.org/10.5402/2012/276520] [PMID: 22919506]
[47]
Wu, Y.C.; Tseng, P.T.; Tu, Y.K.; Hsu, C.Y.; Liang, C.S.; Yeh, T.C.; Chen, T.Y.; Chu, C.S.; Matsuoka, Y.J.; Stubbs, B.; Carvalho, A.F.; Wada, S.; Lin, P.Y.; Chen, Y.W.; Su, K.P. Association of delirium response and safety of pharmacological interventions for the management and prevention of delirium: A network meta-analysis. JAMA Psychiatry, 2019, 76(5), 526-535.
[http://dx.doi.org/10.1001/jamapsychiatry.2018.4365] [PMID: 30810723]
[48]
Zeng, B.S.; Lin, S.Y.; Tu, Y.K.; Wu, Y.C.; Stubbs, B.; Liang, C.S.; Yeh, T.C.; Chen, T.Y.; Carvalho, A.F.; Lin, P.Y.; Lei, W.T.; Hsu, C.W.; Chen, Y.W.; Tseng, P.T.; Chen, C.H. Prevention of postdental procedure bacteremia: A network meta-analysis. J. Dent. Res., 2019, 98(11), 1204-1210.
[http://dx.doi.org/10.1177/0022034519870466] [PMID: 31469596]
[49]
Huang, S.W.; Tsai, C.Y.; Tseng, C.S.; Shih, M.C.; Yeh, Y.C.; Chien, K.L.; Pu, Y.S.; Tu, Y.K. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis. BMJ, 2019, 367, l5919.
[http://dx.doi.org/10.1136/bmj.l5919] [PMID: 31727627]
[50]
Tseng, P.T.; Yang, C.P.; Su, K.P.; Chen, T.Y.; Wu, Y.C.; Tu, Y.K.; Lin, P.Y.; Stubbs, B.; Carvalho, A.F.; Matsuoka, Y.J.; Li, D.J.; Liang, C.S.; Hsu, C.W.; Chen, Y.W.; Shiue, Y.L. The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J. Pineal Res., 2020, 69(2), e12663.
[http://dx.doi.org/10.1111/jpi.12663] [PMID: 32347977]
[51]
Chen, J.J.; Chen, Y.W.; Zeng, B.Y.; Hung, C.M.; Zeng, B.S.; Stubbs, B.; Carvalho, A.F.; Thompson, T.; Roerecke, M.; Su, K.P.; Tu, Y.K.; Wu, Y.C.; Smith, L.; Chen, T.Y.; Lin, P.Y.; Liang, C.S.; Hsu, C.W.; Hsu, S.P.; Kuo, H.C.; Wu, M.K.; Tseng, P.T. Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: A network meta-analysis of randomised controlled trials. Eclini. Med., 2021, 39, 101080.
[http://dx.doi.org/10.1016/j.eclinm.2021.101080] [PMID: 34611615]
[52]
Chen, J.J.; Zeng, B.S.; Wu, C.N.; Stubbs, B.; Carvalho, A.F.; Brunoni, A.R.; Su, K.P.; Tu, Y.K.; Wu, Y.C.; Chen, T.Y.; Lin, P.Y.; Liang, C.S.; Hsu, C.W.; Hsu, S.P.; Kuo, H.C.; Chen, Y.W.; Tseng, P.T.; Li, C.T. Association of central noninvasive brain stimulation interventions with efficacy and safety in tinnitus management: A meta-analysis. JAMA Otolaryngol. Head Neck Surg., 2020, 146(9), 801-809.
[http://dx.doi.org/10.1001/jamaoto.2020.1497] [PMID: 32644131]
[53]
Cheng, Y.S.; Tseng, P.T.; Wu, M.K.; Tu, Y.K.; Wu, Y.C.; Li, D.J.; Chen, T.Y.; Su, K.P.; Stubbs, B.; Carvalho, A.F.; Lin, P.Y.; Matsuoka, Y.J.; Chen, Y.W.; Sun, C.K.; Shiue, Y.L. Pharmacologic and hormonal treatments for menopausal sleep disturbances: A network meta-analysis of 43 randomized controlled trials and 32,271 menopausal women. Sleep Med. Rev., 2021, 57, 101469.
[http://dx.doi.org/10.1016/j.smrv.2021.101469] [PMID: 33836486]
[54]
Cheng, Y.S.; Tseng, P.T.; Wu, Y.C.; Tu, Y.K.; Wu, C.K.; Hsu, C.W.; Lei, W.T.; Li, D.J.; Chen, T.Y.; Stubbs, B.; Carvalho, A.F.; Liang, C.S.; Yeh, T.C.; Chu, C.S.; Chen, Y.W.; Lin, P.Y.; Wu, M.K.; Sun, C.K. Therapeutic benefits of pharmacologic and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: A systematic review and network meta-analysis. J. Psychiatry Neurosci., 2021, 46(1), E196-E207.
[http://dx.doi.org/10.1503/jpn.190122] [PMID: 33497170]
[55]
Wang, H.Y.; Chen, T.Y.; Li, D.J.; Lin, P.Y.; Su, K.P.; Chiang, M.H.; Carvalho, A.F.; Stubbs, B.; Tu, Y.K.; Wu, Y.C.; Roerecke, M.; Smith, L.; Tseng, P.T.; Hung, K.C. Association of pharmacological prophylaxis with the risk of pediatric emergence delirium after sevoflurane anesthesia: An updated network meta-analysis. J. Clin. Anesth., 2021, 75, 110488.
[http://dx.doi.org/10.1016/j.jclinane.2021.110488] [PMID: 34481361]
[56]
Atri, A.; Shaughnessy, L.W.; Locascio, J.J.; Growdon, J.H. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2008, 22(3), 209-221.
[http://dx.doi.org/10.1097/WAD.0b013e31816653bc] [PMID: 18580597]
[57]
Wlodarczyk, J.H.; Brodaty, H.; Hawthorne, G. The relationship between quality of life, Mini-Mental State Examination, and the instrumental activities of daily living in patients with Alzheimer’s disease. Arch. Gerontol. Geriatr., 2004, 39(1), 25-33.
[http://dx.doi.org/10.1016/j.archger.2003.12.004] [PMID: 15158578]
[58]
Perneczky, R.; Wagenpfeil, S.; Komossa, K.; Grimmer, T.; Diehl, J.; Kurz, A. Mapping scores onto stages: Mini-mental state examination and clinical dementia rating. Am. J. Geriatr. Psychiatry, 2006, 14(2), 139-144.
[http://dx.doi.org/10.1097/01.JGP.0000192478.82189.a8] [PMID: 16473978]
[59]
Doody, R.S.; Massman, P.; Dunn, J.K. A method for estimating progression rates in Alzheimer disease. Arch. Neurol., 2001, 58(3), 449-454.
[http://dx.doi.org/10.1001/archneur.58.3.449] [PMID: 11255449]
[60]
Henneges, C.; Reed, C.; Chen, Y.F.; Dell’Agnello, G.; Lebrec, J. Describing the sequence of cognitive decline in Alzheimer’s disease patients: Results from an observational study. J. Alzheimers Dis., 2016, 52(3), 1065-1080.
[http://dx.doi.org/10.3233/JAD-150852] [PMID: 27079700]
[61]
Mohs, R.C.; Knopman, D.; Petersen, R.C.; Ferris, S.H.; Ernesto, C.; Grundman, M.; Sano, M.; Bieliauskas, L.; Geldmacher, D.; Clark, C.; Thal, L.J. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer’s disease assessment scale that broaden its scope. The Alzheimer’s disease cooperative study. Alzheimer Dis. Assoc. Disord., 1997, 11(Suppl. 2), S13-S21.
[http://dx.doi.org/10.1097/00002093-199700112-00003] [PMID: 9236948]
[62]
Higgins, J.; Green, S. Cochrane handbook for systematic reviews of interventions version 5.0.2; The Cochrane Collaboration, 2009.
[63]
Puhan, M.A.; Schünemann, H.J.; Murad, M.H.; Li, T.; Brignardello-Petersen, R.; Singh, J.A.; Kessels, A.G.; Guyatt, G.H.; Group, G.W. A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ, 2014, 349(sep24 5), g5630.
[http://dx.doi.org/10.1136/bmj.g5630] [PMID: 25252733]
[64]
Cipriani, A.; Furukawa, T.A.; Salanti, G.; Chaimani, A.; Atkinson, L.Z.; Ogawa, Y.; Leucht, S.; Ruhe, H.G.; Turner, E.H.; Higgins, J.P.T.; Egger, M.; Takeshima, N.; Hayasaka, Y.; Imai, H.; Shinohara, K.; Tajika, A.; Ioannidis, J.P.A.; Geddes, J.R. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet, 2018, 391(10128), 1357-1366.
[http://dx.doi.org/10.1016/S0140-6736(17)32802-7] [PMID: 29477251]
[65]
Brockhaus, A.C.; Bender, R.; Skipka, G. The Peto odds ratio viewed as a new effect measure. Stat. Med., 2014, 33(28), 4861-4874.
[http://dx.doi.org/10.1002/sim.6301] [PMID: 25244540]
[66]
Cheng, J.; Pullenayegum, E.; Marshall, J.K.; Iorio, A.; Thabane, L. Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: A simulation study. BMJ Open, 2016, 6(8), e010983.
[http://dx.doi.org/10.1136/bmjopen-2015-010983] [PMID: 27531725]
[67]
Tu, Y.K. Use of generalized linear mixed models for network meta-analysis. Med. Decis. Making, 2014, 34(7), 911-918.
[http://dx.doi.org/10.1177/0272989X14545789] [PMID: 25260872]
[68]
Lu, G.; Ades, A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med., 2004, 23(20), 3105-3124.
[http://dx.doi.org/10.1002/sim.1875] [PMID: 15449338]
[69]
Liu, Y.; Wang, W.; Zhang, A.B.; Bai, X.; Zhang, S. Epley and Semont maneuvers for posterior canal benign paroxysmal positional vertigo: A network meta-analysis. Laryngoscope, 2016, 126(4), 951-955.
[http://dx.doi.org/10.1002/lary.25688] [PMID: 26403977]
[70]
Kontopantelis, E.; Springate, D.A.; Reeves, D. A re-analysis of the Cochrane Library data: The dangers of unobserved heterogeneity in meta-analyses. PLoS One, 2013, 8(7), e69930.
[http://dx.doi.org/10.1371/journal.pone.0069930] [PMID: 23922860]
[71]
Salanti, G.; Ades, A.E.; Ioannidis, J.P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol., 2011, 64(2), 163-171.
[http://dx.doi.org/10.1016/j.jclinepi.2010.03.016] [PMID: 20688472]
[72]
Higgins, J.P.; Del Giovane, C.; Chaimani, A.; Caldwell, D.M.; Salanti, G. Evaluating the quality of evidence from a network meta-analysis. Value Health, 2014, 17(7), A324.
[http://dx.doi.org/10.1016/j.jval.2014.08.572] [PMID: 27200533]
[73]
Chaimani, A.; Higgins, J.P.; Mavridis, D.; Spyridonos, P.; Salanti, G. Graphical tools for network meta-analysis in STATA. PLoS One, 2013, 8(10), e76654.
[http://dx.doi.org/10.1371/journal.pone.0076654] [PMID: 24098547]
[74]
Mutz, J.; Vipulananthan, V.; Carter, B.; Hurlemann, R.; Fu, C.H.Y.; Young, A.H. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: Systematic review and network meta-analysis. BMJ, 2019, 364, l1079.
[http://dx.doi.org/10.1136/bmj.l1079] [PMID: 30917990]
[75]
Altman, D.G.; Bland, J.M. Interaction revisited: The difference between two estimates. BMJ, 2003, 326(7382), 219.
[http://dx.doi.org/10.1136/bmj.326.7382.219] [PMID: 12543843]
[76]
Adair, J.C.; Knoefel, J.E.; Morgan, N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology, 2001, 57(8), 1515-1517.
[http://dx.doi.org/10.1212/WNL.57.8.1515] [PMID: 11673605]
[77]
Atri, A.; Frölich, L.; Ballard, C.; Tariot, P.N.; Molinuevo, J.L.; Boneva, N.; Windfeld, K.; Raket, L.L.; Cummings, J.L. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: Three randomized clinical trials. JAMA, 2018, 319(2), 130-142.
[http://dx.doi.org/10.1001/jama.2017.20373] [PMID: 29318278]
[78]
Bloniecki, V.; Aarsland, D.; Blennow, K.; Cummings, J.; Falahati, F.; Winblad, B.; Freund-Levi, Y. Effects of risperidone and galantamine treatment on Alzheimer’s disease biomarker levels in cerebrospinal fluid. J. Alzheimers Dis., 2017, 57(2), 387-393.
[http://dx.doi.org/10.3233/JAD-160758] [PMID: 28269767]
[79]
Bullock, R.; Touchon, J.; Bergman, H.; Gambina, G.; He, Y.; Rapatz, G.; Nagel, J.; Lane, R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr. Med. Res. Opin., 2005, 21(8), 1317-1327.
[http://dx.doi.org/10.1185/030079905X56565] [PMID: 16083542]
[80]
Connelly, P.J.; Prentice, N.P.; Cousland, G.; Bonham, J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2008, 23(2), 155-160.
[http://dx.doi.org/10.1002/gps.1856] [PMID: 17600848]
[81]
Cummings, J.; Froelich, L.; Black, S.E.; Bakchine, S.; Bellelli, G.; Molinuevo, J.L.; Kressig, R.W.; Downs, P.; Caputo, A.; Strohmaier, C. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord., 2012, 33(5), 341-353.
[http://dx.doi.org/10.1159/000340056] [PMID: 22796905]
[82]
Devore, E.E.; Harrison, S.L.; Stone, K.L.; Holton, K.F.; Barrett-Connor, E.; Ancoli-Israel, S.; Yaffe, K.; Ensrud, K.; Cawthon, P.M.; Redline, S.; Orwoll, E.; Schernhammer, E.S. Association of urinary melatonin levels and aging-related outcomes in older men. Sleep Med., 2016, 23, 73-80.
[http://dx.doi.org/10.1016/j.sleep.2016.07.006] [PMID: 27692280]
[83]
Doody, R.S.; Gavrilova, S.I.; Sano, M.; Thomas, R.G.; Aisen, P.S.; Bachurin, S.O.; Seely, L.; Hung, D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: A randomised, double-blind, placebo-controlled study. Lancet, 2008, 372(9634), 207-215.
[http://dx.doi.org/10.1016/S0140-6736(08)61074-0] [PMID: 18640457]
[84]
Dowling, G.A.; Burr, R.L.; Van Someren, E.J.; Hubbard, E.M.; Luxenberg, J.S.; Mastick, J.; Cooper, B.A. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease. J. Am. Geriatr. Soc., 2008, 56(2), 239-246.
[http://dx.doi.org/10.1111/j.1532-5415.2007.01543.x] [PMID: 18070004]
[85]
Fan, Y.; Yuan, L.; Ji, M.; Yang, J.; Gao, D. The effect of melatonin on early postoperative cognitive decline in elderly patients undergoing hip arthroplasty: A randomized controlled trial. J. Clin. Anesth., 2017, 39, 77-81.
[http://dx.doi.org/10.1016/j.jclinane.2017.03.023] [PMID: 28494914]
[86]
Feldman, H.H.; Lane, R.; Study, G. Rivastigmine: A placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 2007, 78(10), 1056-1063.
[http://dx.doi.org/10.1136/jnnp.2006.099424] [PMID: 17353259]
[87]
Frölich, L.; Ashwood, T.; Nilsson, J.; Eckerwall, G.; Sirocco, I. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer’s disease: A phase IIb dose-finding study. J. Alzheimers Dis., 2011, 24(2), 363-374.
[http://dx.doi.org/10.3233/JAD-2011-101554] [PMID: 21258153]
[88]
Frölich, L.; Atri, A.; Ballard, C.; Tariot, P.N.; Molinuevo, J.L.; Boneva, N.; Geist, M.A.; Raket, L.L.; Cummings, J.L. Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate Alzheimer’s disease. J. Alzheimers Dis., 2019, 67(1), 303-313.
[http://dx.doi.org/10.3233/JAD-180595] [PMID: 30636738]
[89]
Fullerton, T.; Binneman, B.; David, W.; Delnomdedieu, M.; Kupiec, J.; Lockwood, P.; Mancuso, J.; Miceli, J.; Bell, J. A phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil. Alzheimers Res. Ther., 2018, 10(1), 38.
[http://dx.doi.org/10.1186/s13195-018-0368-9] [PMID: 29622037]
[90]
Garzón, C.; Guerrero, J.M.; Aramburu, O.; Guzmán, T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: A randomized, double-blind, placebo-controlled study. Aging Clin. Exp. Res., 2009, 21(1), 38-42.
[http://dx.doi.org/10.1007/BF03324897] [PMID: 19225268]
[91]
Gault, L.M.; Lenz, R.A.; Ritchie, C.W.; Meier, A.; Othman, A.A.; Tang, Q.; Berry, S.; Pritchett, Y.; Robieson, W.Z. ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: Randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res. Ther., 2016, 8(1), 44.
[http://dx.doi.org/10.1186/s13195-016-0210-1] [PMID: 27756421]
[92]
Gault, L.M.; Ritchie, C.W.; Robieson, W.Z.; Pritchett, Y.; Othman, A.A.; Lenz, R.A. A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer’s dementia. Alzheimers Dement. (N. Y.), 2015, 1(1), 81-90.
[http://dx.doi.org/10.1016/j.trci.2015.06.001] [PMID: 29854928]
[93]
Gehrman, P.R.; Connor, D.J.; Martin, J.L.; Shochat, T.; Corey-Bloom, J.; Ancoli-Israel, S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am. J. Geriatr. Psychiatry, 2009, 17(2), 166-169.
[http://dx.doi.org/10.1097/JGP.0b013e318187de18] [PMID: 19155748]
[94]
Grossberg, G.T.; Alva, G.; Hendrix, S.; Ellison, N.; Kane, M.C.; Edwards, J.; Memantine, E.R. Memantine ER maintains patient response in moderate to severe Alzheimer’s disease: Post hoc analyses from a randomized, controlled, clinical trial of patients treated with cholinesterase inhibitors. Alzheimer Dis. Assoc. Disord., 2018, 32(3), 173-178.
[http://dx.doi.org/10.1097/WAD.0000000000000261] [PMID: 29771687]
[95]
Haffmans, P.M.; Sival, R.C.; Lucius, S.A.; Cats, Q.; van Gelder, L. Bright light therapy and melatonin in motor restless behaviour in dementia: A placebo-controlled study. Int. J. Geriatr. Psychiatry, 2001, 16(1), 106-110.
[http://dx.doi.org/10.1002/1099-1166(200101)16:1<106::AID-GPS288>3.0.CO;2-9] [PMID: 11180494]
[96]
Haig, G.M.; Pritchett, Y.; Meier, A.; Othman, A.A.; Hall, C.; Gault, L.M.; Lenz, R.A. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia. J. Alzheimers Dis., 2014, 42(3), 959-971.
[http://dx.doi.org/10.3233/JAD-140291] [PMID: 25024314]
[97]
Hamdieh, M.; Abbasinazari, M.; Badri, T.; Saberi-Isfeedvajani, M.; Arzani, G. The impact of melatonin on the alleviation of cognitive impairment during electroconvulsive therapy: A double-blind controlled trial. Neurol. Psychiatry Brain Res., 2017, 24, 30-34.
[http://dx.doi.org/10.1016/j.npbr.2017.04.002]
[98]
Hong, Y.J.; Choi, S.H.; Jeong, J.H.; Park, K.W.; Na, H.R. Effectiveness of anti-dementia drugs in extremely severe Alzheimer’s disease: A 12-week, multicenter, randomized, single-blind study. J. Alzheimers Dis., 2018, 63(3), 1035-1044.
[http://dx.doi.org/10.3233/JAD-180159] [PMID: 29710726]
[99]
Hong, Y.J.; Han, H.J.; Youn, Y.C.; Park, K.W.; Yang, D.W.; Kim, S.; Kim, H.J.; Kim, J.E.; Lee, J.H. Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: A multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. Alzheimers Res. Ther., 2019, 11(1), 37.
[http://dx.doi.org/10.1186/s13195-019-0492-1] [PMID: 31039806]
[100]
Howard, R.; McShane, R.; Lindesay, J.; Ritchie, C.; Baldwin, A.; Barber, R.; Burns, A.; Dening, T.; Findlay, D.; Holmes, C.; Hughes, A.; Jacoby, R.; Jones, R.; Jones, R.; McKeith, I.; Macharouthu, A.; O’Brien, J.; Passmore, P.; Sheehan, B.; Juszczak, E.; Katona, C.; Hills, R.; Knapp, M.; Ballard, C.; Brown, R.; Banerjee, S.; Onions, C.; Griffin, M.; Adams, J.; Gray, R.; Johnson, T.; Bentham, P.; Phillips, P. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N. Engl. J. Med., 2012, 366(10), 893-903.
[http://dx.doi.org/10.1056/NEJMoa1106668] [PMID: 22397651]
[101]
Huisa, B.N.; Thomas, R.G.; Jin, S.; Oltersdorf, T.; Taylor, C.; Feldman, H.H. Memantine and acetylcholinesterase inhibitor use in Alzheimer’s disease clinical trials: Potential for confounding by indication. J. Alzheimers Dis., 2019, 67(2), 707-713.
[http://dx.doi.org/10.3233/JAD-180684] [PMID: 30636733]
[102]
Jaiswal, S.J.; McCarthy, T.J.; Wineinger, N.E.; Kang, D.Y.; Song, J.; Garcia, S.; van Niekerk, C.J.; Lu, C.Y.; Loeks, M.; Owens, R.L. Melatonin and sleep in preventing hospitalized delirium: A randomized clinical trial. Am. J. Med., 2018, 131(9), 1110-1117.e4.
[http://dx.doi.org/10.1016/j.amjmed.2018.04.009] [PMID: 29729237]
[103]
Johannsen, P.; Salmon, E.; Hampel, H.; Xu, Y.; Richardson, S.; Qvitzau, S.; Schindler, R.; Group, A.S. Assessing therapeutic efficacy in a progressive disease: A study of donepezil in Alzheimer’s disease. CNS Drugs, 2006, 20(4), 311-325.
[http://dx.doi.org/10.2165/00023210-200620040-00005] [PMID: 16599649]
[104]
Ma, Y.; Ji, J.; Li, G.; Yang, S.; Pan, S. Effects of donepezil on cognitive functions and the expression level of β-amyloid in peripheral blood of patients with Alzheimer’s disease. Exp. Ther. Med., 2018, 15(2), 1875-1878.
[PMID: 29434777]
[105]
Maher-Edwards, G.; Zvartau-Hind, M.; Hunter, A.J.; Gold, M.; Hopton, G.; Jacobs, G.; Davy, M.; Williams, P. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Curr. Alzheimer Res., 2010, 7(5), 374-385.
[http://dx.doi.org/10.2174/156720510791383831] [PMID: 20043816]
[106]
Manni, R.; Cremascoli, R.; Perretti, C.; De Icco, R.; Picascia, M.; Ghezzi, C.; Cerri, S.; Sinforiani, E.; Terzaghi, M. Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity. Sleep Med., 2019, 63, 122-126.
[http://dx.doi.org/10.1016/j.sleep.2019.04.018] [PMID: 31622953]
[107]
Mintzer, J.E.; Tune, L.E.; Breder, C.D.; Swanink, R.; Marcus, R.N.; McQuade, R.D.; Forbes, A. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am. J. Geriatr. Psychiatry, 2007, 15(11), 918-931.
[http://dx.doi.org/10.1097/JGP.0b013e3181557b47] [PMID: 17974864]
[108]
Montero-Odasso, M.; Speechley, M.; Chertkow, H.; Sarquis-Adamson, Y.; Wells, J.; Borrie, M.; Vanderhaeghe, L.; Zou, G.Y.; Fraser, S.; Bherer, L.; Muir-Hunter, S.W. Donepezil for gait and falls in mild cognitive impairment: A randomized controlled trial. Eur. J. Neurol., 2019, 26(4), 651-659.
[http://dx.doi.org/10.1111/ene.13872] [PMID: 30565793]
[109]
Mulnard, R.A.; Cotman, C.W.; Kawas, C.; van Dyck, C.H.; Sano, M.; Doody, R.; Koss, E.; Pfeiffer, E.; Jin, S.; Gamst, A.; Grundman, M.; Thomas, R.; Thal, L.J. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA, 2000, 283(8), 1007-1015.
[http://dx.doi.org/10.1001/jama.283.8.1007] [PMID: 10697060]
[110]
Nakamura, Y.; Kitamura, S.; Homma, A.; Shiosakai, K.; Matsui, D. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: Results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opin. Pharmacother., 2014, 15(7), 913-925.
[http://dx.doi.org/10.1517/14656566.2014.902446] [PMID: 24673497]
[111]
Petersen, R.C.; Thomas, R.G.; Grundman, M.; Bennett, D.; Doody, R.; Ferris, S.; Galasko, D.; Jin, S.; Kaye, J.; Levey, A.; Pfeiffer, E.; Sano, M.; van Dyck, C.H.; Thal, L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med., 2005, 352(23), 2379-2388.
[http://dx.doi.org/10.1056/NEJMoa050151] [PMID: 15829527]
[112]
Reisberg, B.; Doody, R.; Stöffler, A.; Schmitt, F.; Ferris, S.; Möbius, H.J. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol., 2006, 63(1), 49-54.
[http://dx.doi.org/10.1001/archneur.63.1.49] [PMID: 16401736]
[113]
Rockwood, K.; Mintzer, J.; Truyen, L.; Wessel, T.; Wilkinson, D. Effects of a flexible galantamine dose in Alzheimer’s disease: A randomised, controlled trial. J. Neurol. Neurosurg. Psychiatry, 2001, 71(5), 589-595.
[http://dx.doi.org/10.1136/jnnp.71.5.589] [PMID: 11606667]
[114]
Rogers, S.L.; Doody, R.S.; Mohs, R.C.; Friedhoff, L.T. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch. Intern. Med., 1998, 158(9), 1021-1031.
[http://dx.doi.org/10.1001/archinte.158.9.1021] [PMID: 9588436]
[115]
Rondanelli, M.; Opizzi, A.; Faliva, M.; Mozzoni, M.; Antoniello, N.; Cazzola, R.; Savarè, R.; Cerutti, R.; Grossi, E.; Cestaro, B. Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. Nutr. Neurosci., 2012, 15(2), 46-54.
[http://dx.doi.org/10.1179/1476830511Y.0000000032] [PMID: 22334085]
[116]
Sano, M.; Bell, K.L.; Galasko, D.; Galvin, J.E.; Thomas, R.G.; van Dyck, C.H.; Aisen, P.S. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology, 2011, 77(6), 556-563.
[http://dx.doi.org/10.1212/WNL.0b013e318228bf11] [PMID: 21795660]
[117]
Santoro, A.; Siviero, P.; Minicuci, N.; Bellavista, E.; Mishto, M.; Olivieri, F.; Marchegiani, F.; Chiamenti, A.M.; Benussi, L.; Ghidoni, R.; Nacmias, B.; Bagnoli, S.; Ginestroni, A.; Scarpino, O.; Feraco, E.; Gianni, W.; Cruciani, G.; Paganelli, R.; Di Iorio, A.; Scognamiglio, M.; Grimaldi, L.M.; Gabelli, C.; Sorbi, S.; Binetti, G.; Crepaldi, G.; Franceschi, C. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study. CNS Drugs, 2010, 24(2), 163-176.
[http://dx.doi.org/10.2165/11310960-000000000-00000] [PMID: 20088621]
[118]
Serfaty, M.; Kennell-Webb, S.; Warner, J.; Blizard, R.; Raven, P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int. J. Geriatr. Psychiatry, 2002, 17(12), 1120-1127.
[http://dx.doi.org/10.1002/gps.760] [PMID: 12461760]
[119]
Simons, M.; Schwärzler, F.; Lütjohann, D.; von Bergmann, K.; Beyreuther, K.; Dichgans, J.; Wormstall, H.; Hartmann, T.; Schulz, J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol., 2002, 52(3), 346-350.
[http://dx.doi.org/10.1002/ana.10292] [PMID: 12205648]
[120]
Soler, A.; Amer, G.; Leiva, A.; Ripoll, J.; Llorente, M.A.; Leiva, A.; Taltavull, J.M.; Molina, R.; Llobera, J. Continuation versus discontinuation of treatment for severe dementia: Randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM). BMC Geriatr., 2019, 19(1), 101.
[http://dx.doi.org/10.1186/s12877-019-1122-2] [PMID: 30971215]
[121]
Thal, L.J.; Grundman, M.; Berg, J.; Ernstrom, K.; Margolin, R.; Pfeiffer, E.; Weiner, M.F.; Zamrini, E.; Thomas, R.G. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology, 2003, 61(11), 1498-1502.
[http://dx.doi.org/10.1212/01.WNL.0000096376.03678.C1] [PMID: 14663031]
[122]
Wang, P.N.; Liao, S.Q.; Liu, R.S.; Liu, C.Y.; Chao, H.T.; Lu, S.R.; Yu, H.Y.; Wang, S.J.; Liu, H.C. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology, 2000, 54(11), 2061-2066.
[http://dx.doi.org/10.1212/WNL.54.11.2061] [PMID: 10851363]
[123]
Winblad, B.; Grossberg, G.; Frölich, L.; Farlow, M.; Zechner, S.; Nagel, J.; Lane, R. IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology, 2007, 69(4)(Suppl. 1), S14-S22.
[http://dx.doi.org/10.1212/01.wnl.0000281847.17519.e0] [PMID: 17646619]
[124]
Zhang, Z.; Wang, X.; Chen, Q.; Shu, L.; Wang, J.; Shan, G. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi Xue Za Zhi, 2002, 82(14), 941-944.
[PMID: 12181083]
[125]
Zhou, T.; Wang, J.; Xin, C.; Kong, L.; Wang, C. Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: A clinical trial. Exp. Ther. Med., 2019, 17(3), 1625-1630.
[PMID: 30783429]
[126]
Glass, O.M.; Hermida, A.P.; Hershenberg, R.; Schwartz, A.C. Considerations and current trends in the management of the geriatric patient on a consultation-liaison service. Curr. Psychiatry Rep., 2020, 22(5), 21.
[http://dx.doi.org/10.1007/s11920-020-01147-2] [PMID: 32285305]
[127]
Xu, L.; Yu, H.; Sun, H.; Hu, B.; Geng, Y. Dietary melatonin therapy alleviates the lamina cribrosa damages in patients with mild cognitive impairments: A double-blinded, randomized controlled study. Med. Sci. Monit., 2020, 26, e923232.
[http://dx.doi.org/10.12659/MSM.923232] [PMID: 32376818]
[128]
Bakchine, S.; Loft, H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J. Alzheimers Dis., 2008, 13(1), 97-107.
[http://dx.doi.org/10.3233/JAD-2008-13110] [PMID: 18334761]
[129]
Black, S.E.; Doody, R.; Li, H.; McRae, T.; Jambor, K.M.; Xu, Y.; Sun, Y.; Perdomo, C.A.; Richardson, S. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology, 2007, 69(5), 459-469.
[http://dx.doi.org/10.1212/01.wnl.0000266627.96040.5a] [PMID: 17664405]
[130]
Brodaty, H.; Corey-Bloom, J.; Potocnik, F.C.; Truyen, L.; Gold, M.; Damaraju, C.R. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement. Geriatr. Cogn. Disord., 2005, 20(2-3), 120-132.
[http://dx.doi.org/10.1159/000086613] [PMID: 15990426]
[131]
Burns, A.; Bernabei, R.; Bullock, R.; Cruz Jentoft, A.J.; Frölich, L.; Hock, C.; Raivio, M.; Triau, E.; Vandewoude, M.; Wimo, A.; Came, E.; Van Baelen, B.; Hammond, G.L.; van Oene, J.C.; Schwalen, S. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol., 2009, 8(1), 39-47.
[http://dx.doi.org/10.1016/S1474-4422(08)70261-8] [PMID: 19042161]
[132]
Burns, A.; Rossor, M.; Hecker, J.; Gauthier, S.; Petit, H.; Möller, H.J.; Rogers, S.L.; Friedhoff, L.T. The effects of donepezil in Alzheimer’s disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord., 1999, 10(3), 237-244.
[http://dx.doi.org/10.1159/000017126] [PMID: 10325453]
[133]
Dysken, M.W.; Sano, M.; Asthana, S.; Vertrees, J.E.; Pallaki, M.; Llorente, M.; Love, S.; Schellenberg, G.D.; McCarten, J.R.; Malphurs, J.; Prieto, S.; Chen, P.; Loreck, D.J.; Trapp, G.; Bakshi, R.S.; Mintzer, J.E.; Heidebrink, J.L.; Vidal-Cardona, A.; Arroyo, L.M.; Cruz, A.R.; Zachariah, S.; Kowall, N.W.; Chopra, M.P.; Craft, S.; Thielke, S.; Turvey, C.L.; Woodman, C.; Monnell, K.A.; Gordon, K.; Tomaska, J.; Segal, Y.; Peduzzi, P.N.; Guarino, P.D. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA, 2014, 311(1), 33-44.
[http://dx.doi.org/10.1001/jama.2013.282834] [PMID: 24381967]
[134]
Farlow, M.R.; Grossberg, G.T.; Sadowsky, C.H.; Meng, X.; Somogyi, M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia. CNS Neurosci. Ther., 2013, 19(10), 745-752.
[http://dx.doi.org/10.1111/cns.12158] [PMID: 23924050]
[135]
Farlow, M.R.; Salloway, S.; Tariot, P.N.; Yardley, J.; Moline, M.L.; Wang, Q.; Brand-Schieber, E.; Zou, H.; Hsu, T.; Satlin, A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin. Ther., 2010, 32(7), 1234-1251.
[http://dx.doi.org/10.1016/j.clinthera.2010.06.019] [PMID: 20678673]
[136]
Feldman, H.; Gauthier, S.; Hecker, J.; Vellas, B.; Subbiah, P.; Whalen, E.; Donepezil, M.S.I.G. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology, 2001, 57(4), 613-620.
[http://dx.doi.org/10.1212/WNL.57.4.613] [PMID: 11524468]
[137]
Forette, F.; Anand, R.; Gharabawi, G. A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur. J. Neurol., 1999, 6(4), 423-429.
[http://dx.doi.org/10.1046/j.1468-1331.1999.640423.x] [PMID: 10362894]
[138]
Fox, C.; Crugel, M.; Maidment, I.; Auestad, B.H.; Coulton, S.; Treloar, A.; Ballard, C.; Boustani, M.; Katona, C.; Livingston, G. Efficacy of memantine for agitation in Alzheimer’s dementia: A randomised double-blind placebo controlled trial. PLoS One, 2012, 7(5), e35185.
[http://dx.doi.org/10.1371/journal.pone.0035185] [PMID: 22567095]
[139]
Grossberg, G.T.; Manes, F.; Allegri, R.F.; Gutiérrez-Robledo, L.M.; Gloger, S.; Xie, L.; Jia, X.D.; Pejović, V.; Miller, M.L.; Perhach, J.L.; Graham, S.M. The safety, tolerability, and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs, 2013, 27(6), 469-478.
[http://dx.doi.org/10.1007/s40263-013-0077-7] [PMID: 23733403]
[140]
Hager, K.; Baseman, A.S.; Nye, J.S.; Brashear, H.R.; Han, J.; Sano, M.; Davis, B.; Richards, H.M. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr. Dis. Treat., 2014, 10, 391-401.
[PMID: 24591834]
[141]
Herrmann, N.; Gauthier, S.; Boneva, N.; Lemming, O.M. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer’s disease. Int. Psychogeriatr., 2013, 25(6), 919-927.
[http://dx.doi.org/10.1017/S1041610213000239] [PMID: 23472619]
[142]
Homma, A.; Atarashi, H.; Kubota, N.; Nakai, K.; Takase, T. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in japanese patients with severe Alzheimer’s disease: A randomized, double-blind trial. J. Alzheimers Dis., 2016, 52(1), 345-357.
[http://dx.doi.org/10.3233/JAD-151149] [PMID: 26967222]
[143]
Homma, A.; Imai, Y.; Tago, H.; Asada, T.; Shigeta, M.; Iwamoto, T.; Takita, M.; Arimoto, I.; Koma, H.; Ohbayashi, T. Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement. Geriatr. Cogn. Disord., 2008, 25(5), 399-407.
[http://dx.doi.org/10.1159/000122961] [PMID: 18391486]
[144]
Homma, A.; Takeda, M.; Imai, Y.; Udaka, F.; Hasegawa, K.; Kameyama, M.; Nishimura, T. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement. Geriatr. Cogn. Disord., 2000, 11(6), 299-313.
[http://dx.doi.org/10.1159/000017259] [PMID: 11044775]
[145]
Howard, R.J.; Juszczak, E.; Ballard, C.G.; Bentham, P.; Brown, R.G.; Bullock, R.; Burns, A.S.; Holmes, C.; Jacoby, R.; Johnson, T.; Knapp, M.; Lindesay, J.; O’Brien, J.T.; Wilcock, G.; Katona, C.; Jones, R.W.; DeCesare, J.; Rodger, M. Donepezil for the treatment of agitation in Alzheimer’s disease. N. Engl. J. Med., 2007, 357(14), 1382-1392.
[http://dx.doi.org/10.1056/NEJMoa066583] [PMID: 17914039]
[146]
Jia, J.; Wei, C.; Jia, L.; Tang, Y.; Liang, J.; Zhou, A.; Li, F.; Shi, L.; Doody, R.S. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer’s disease: A randomized controlled trial. J. Alzheimers Dis., 2017, 56(4), 1495-1504.
[http://dx.doi.org/10.3233/JAD-161117] [PMID: 28157100]
[147]
Karaman, Y.; Erdoğan, F.; Köseoğlu, E.; Turan, T.; Ersoy, A.O. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer’s disease. Dement. Geriatr. Cogn. Disord., 2005, 19(1), 51-56.
[http://dx.doi.org/10.1159/000080972] [PMID: 15383747]
[148]
Krishnan, K.R.; Charles, H.C.; Doraiswamy, P.M.; Mintzer, J.; Weisler, R.; Yu, X.; Perdomo, C.; Ieni, J.R.; Rogers, S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am. J. Psychiatry, 2003, 160(11), 2003-2011.
[http://dx.doi.org/10.1176/appi.ajp.160.11.2003] [PMID: 14594748]
[149]
Likitjaroen, Y.; Meindl, T.; Friese, U.; Wagner, M.; Buerger, K.; Hampel, H.; Teipel, S.J. Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: A 12-month randomized, placebo-controlled, double-blinded study. Eur. Arch. Psychiatry Clin. Neurosci., 2012, 262(4), 341-350.
[http://dx.doi.org/10.1007/s00406-011-0234-2] [PMID: 21818628]
[150]
Maher-Edwards, G.; Dixon, R.; Hunter, J.; Gold, M.; Hopton, G.; Jacobs, G.; Hunter, J.; Williams, P. SB-742457 and donepezil in Alzheimer disease: A randomized, placebo-controlled study. Int. J. Geriatr. Psychiatry, 2011, 26(5), 536-544.
[http://dx.doi.org/10.1002/gps.2562] [PMID: 20872778]
[151]
Nakamura, Y.; Imai, Y.; Shigeta, M.; Graf, A.; Shirahase, T.; Kim, H.; Fujii, A.; Mori, J.; Homma, A. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. Extra, 2011, 1(1), 163-179.
[http://dx.doi.org/10.1159/000328929] [PMID: 22163242]
[152]
Peskind, E.R.; Potkin, S.G.; Pomara, N.; Ott, B.R.; Graham, S.M.; Olin, J.T.; McDonald, S. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am. J. Geriatr. Psychiatry, 2006, 14(8), 704-715.
[http://dx.doi.org/10.1097/01.JGP.0000224350.82719.83] [PMID: 16861375]
[153]
Porsteinsson, A.P.; Grossberg, G.T.; Mintzer, J.; Olin, J.T.; Memantine, M.E.M.M.D.S.G. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res., 2008, 5(1), 83-89.
[http://dx.doi.org/10.2174/156720508783884576] [PMID: 18288936]
[154]
Raskind, M.A.; Peskind, E.R.; Wessel, T.; Yuan, W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology, 2000, 54(12), 2261-2268.
[http://dx.doi.org/10.1212/WNL.54.12.2261] [PMID: 10881250]
[155]
Reisberg, B.; Doody, R.; Stöffler, A.; Schmitt, F.; Ferris, S.; Möbius, H.J. Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med., 2003, 348(14), 1333-1341.
[http://dx.doi.org/10.1056/NEJMoa013128] [PMID: 12672860]
[156]
Rockwood, K.; Fay, S.; Song, X.; MacKnight, C.; Gorman, M. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: A randomized controlled trial. CMAJ, 2006, 174(8), 1099-1105.
[http://dx.doi.org/10.1503/cmaj.051432] [PMID: 16554498]
[157]
Rogers, S.L.; Farlow, M.R.; Doody, R.S.; Mohs, R.; Friedhoff, L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology, 1998, 50(1), 136-145.
[http://dx.doi.org/10.1212/WNL.50.1.136] [PMID: 9443470]
[158]
Rösler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stähelin, H.B.; Hartman, R.; Gharabawi, M.; Bayer, T. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomised controlled trial. BMJ, 1999, 318(7184), 633-638.
[http://dx.doi.org/10.1136/bmj.318.7184.633] [PMID: 10066203]
[159]
Seltzer, B.; Zolnouni, P.; Nunez, M.; Goldman, R.; Kumar, D.; Ieni, J.; Richardson, S. Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Arch. Neurol., 2004, 61(12), 1852-1856.
[http://dx.doi.org/10.1001/archneur.61.12.1852] [PMID: 15596605]
[160]
Shao, Z.Q. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer’s disease. Int. J. Clin. Exp. Med., 2015, 8(2), 2944-2948.
[PMID: 25932260]
[161]
Tariot, P.N.; Cummings, J.L.; Katz, I.R.; Mintzer, J.; Perdomo, C.A.; Schwam, E.M.; Whalen, E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J. Am. Geriatr. Soc., 2001, 49(12), 1590-1599.
[http://dx.doi.org/10.1111/j.1532-5415.2001.49266.x] [PMID: 11843990]
[162]
Tariot, P.N.; Farlow, M.R.; Grossberg, G.T.; Graham, S.M.; McDonald, S.; Gergel, I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA, 2004, 291(3), 317-324.
[http://dx.doi.org/10.1001/jama.291.3.317] [PMID: 14734594]
[163]
Tariot, P.N.; Solomon, P.R.; Morris, J.C.; Kershaw, P.; Lilienfeld, S.; Ding, C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 2000, 54(12), 2269-2276.
[http://dx.doi.org/10.1212/WNL.54.12.2269] [PMID: 10881251]
[164]
Tune, L.; Tiseo, P.J.; Ieni, J.; Perdomo, C.; Pratt, R.D.; Votaw, J.R.; Jewart, R.D.; Hoffman, J.M. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: Results of a 24-week, double-blind, placebo-controlled study. Am. J. Geriatr. Psychiatry, 2003, 11(2), 169-177.
[http://dx.doi.org/10.1097/00019442-200303000-00007] [PMID: 12611746]
[165]
van Dyck, C.H.; Tariot, P.N.; Meyers, B.; Malca Resnick, E.; Memantine, M.E.M.M.D.S.G. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2007, 21(2), 136-143.
[http://dx.doi.org/10.1097/WAD.0b013e318065c495] [PMID: 17545739]
[166]
Vila-Castelar, C.; Ly, J.J.; Kaplan, L.; Van Dyk, K.; Berger, J.T.; Macina, L.O.; Stewart, J.L.; Foldi, N.S. Attention measures of accuracy, variability, and fatigue detect early response to donepezil in Alzheimer’s disease: A randomized, double-blind, placebo-controlled pilot trial. Arch. Clin. Neuropsychol., 2019, 34(3), 277-289.
[http://dx.doi.org/10.1093/arclin/acy032] [PMID: 29635383]
[167]
Wang, T.; Huang, Q.; Reiman, E.M.; Chen, K.; Li, X.; Li, G.; Lin, Z.; Li, C.; Xiao, S. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J. Clin. Psychopharmacol., 2013, 33(5), 636-642.
[http://dx.doi.org/10.1097/JCP.0b013e31829a876a] [PMID: 23948786]
[168]
Wilcock, G.K.; Lilienfeld, S.; Gaens, E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ, 2000, 321(7274), 1445-1449.
[http://dx.doi.org/10.1136/bmj.321.7274.1445] [PMID: 11110737]
[169]
Wilkinson, D.; Murray, J. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2001, 16(9), 852-857.
[http://dx.doi.org/10.1002/gps.409] [PMID: 11571763]
[170]
Winblad, B.; Cummings, J.; Andreasen, N.; Grossberg, G.; Onofrj, M.; Sadowsky, C.; Zechner, S.; Nagel, J.; Lane, R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease--rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry, 2007, 22(5), 456-467.
[http://dx.doi.org/10.1002/gps.1788] [PMID: 17380489]
[171]
Winblad, B.; Kilander, L.; Eriksson, S.; Minthon, L.; Båtsman, S.; Wetterholm, A.L.; Jansson-Blixt, C.; Haglund, A. Donepezil in patients with severe Alzheimer’s disease: Double-blind, parallel-group, placebo-controlled study. Lancet, 2006, 367(9516), 1057-1065.
[http://dx.doi.org/10.1016/S0140-6736(06)68350-5] [PMID: 16581404]
[172]
Zhang, N.; Wei, C.; Du, H.; Shi, F.D.; Cheng, Y. The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer’s disease patients. Dement. Geriatr. Cogn. Disord., 2015, 40(1-2), 85-93.
[http://dx.doi.org/10.1159/000430808] [PMID: 26066622]
[173]
Zhang, Z.X.; Hong, Z.; Wang, Y.P.; He, L.; Wang, N.; Zhao, Z.X.; Zhao, G.; Shang, L.; Weisskopf, M.; Callegari, F.; Strohmaier, C. Rivastigmine patch in Chinese patients with probable Alzheimer’s disease: A 24-week, randomized, double-blind parallel-group study comparing rivastigmine patch (9.5 mg/24 h) with capsule (6 mg twice daily). CNS Neurosci. Ther., 2016, 22(6), 488-496.
[http://dx.doi.org/10.1111/cns.12521] [PMID: 27012596]
[174]
Hughes, R.J.; Sack, R.L.; Lewy, A.J. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: Assessment in a clinical trial of melatonin replacement. Sleep, 1998, 21(1), 52-68.
[PMID: 9485533]
[175]
Morales-Delgado, R.; Cámara-Lemarroy, C.R.; Salinas-Martínez, R.; Gámez-Treviño, D.; Arredondo-Jaime, A.; Hernández-Maldonado, E.; Guajardo-Álvarez, G. A randomized placebo-controlled trial evaluating the effect of melatonin on sleep quality in patients with mild-moderate dementia. Eur. Geriatr. Med., 2018, 9(4), 449-454.
[http://dx.doi.org/10.1007/s41999-018-0068-9] [PMID: 34674490]
[176]
Swaab, D.F.; Roozendaal, B.; Ravid, R.; Velis, D.N.; Gooren, L.; Williams, R.S. Suprachiasmatic nucleus in aging, Alzheimer’s disease, transsexuality and Prader-Willi syndrome. Prog. Brain Res., 1987, 72, 301-310.
[http://dx.doi.org/10.1016/S0079-6123(08)60216-2] [PMID: 3615902]
[177]
Swaab, D.F.; Fliers, E.; Partiman, T.S. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res., 1985, 342(1), 37-44.
[http://dx.doi.org/10.1016/0006-8993(85)91350-2] [PMID: 4041816]
[178]
Volicer, L.; Harper, D.G.; Manning, B.C.; Goldstein, R.; Satlin, A. Sundowning and circadian rhythms in Alzheimer’s disease. Am. J. Psychiatry, 2001, 158(5), 704-711.
[http://dx.doi.org/10.1176/appi.ajp.158.5.704] [PMID: 11329390]
[179]
Ancoli-Israel, S.; Klauber, M.R.; Jones, D.W.; Kripke, D.F.; Martin, J.; Mason, W.; Pat-Horenczyk, R.; Fell, R. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep, 1997, 20(1), 18-23.
[PMID: 9130329]
[180]
Bonanni, E.; Maestri, M.; Tognoni, G.; Fabbrini, M.; Nucciarone, B.; Manca, M.L.; Gori, S.; Iudice, A.; Murri, L. Daytime sleepiness in mild and moderate Alzheimer’s disease and its relationship with cognitive impairment. J. Sleep Res., 2005, 14(3), 311-317.
[http://dx.doi.org/10.1111/j.1365-2869.2005.00462.x] [PMID: 16120107]
[181]
Ju, Y.E.; Lucey, B.P.; Holtzman, D.M. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat. Rev. Neurol., 2014, 10(2), 115-119.
[http://dx.doi.org/10.1038/nrneurol.2013.269] [PMID: 24366271]
[182]
Lim, A.S.; Yu, L.; Kowgier, M.; Schneider, J.A.; Buchman, A.S.; Bennett, D.A. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol., 2013, 70(12), 1544-1551.
[http://dx.doi.org/10.1001/jamaneurol.2013.4215] [PMID: 24145819]
[183]
Ju, Y.E.; McLeland, J.S.; Toedebusch, C.D.; Xiong, C.; Fagan, A.M.; Duntley, S.P.; Morris, J.C.; Holtzman, D.M. Sleep quality and preclinical Alzheimer disease. JAMA Neurol., 2013, 70(5), 587-593.
[http://dx.doi.org/10.1001/jamaneurol.2013.2334] [PMID: 23479184]
[184]
Spira, A.P.; Gamaldo, A.A.; An, Y.; Wu, M.N.; Simonsick, E.M.; Bilgel, M.; Zhou, Y.; Wong, D.F.; Ferrucci, L.; Resnick, S.M. Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol., 2013, 70(12), 1537-1543.
[http://dx.doi.org/10.1001/jamaneurol.2013.4258] [PMID: 24145859]
[185]
Xie, L.; Kang, H.; Xu, Q.; Chen, M.J.; Liao, Y.; Thiyagarajan, M.; O’Donnell, J.; Christensen, D.J.; Nicholson, C.; Iliff, J.J.; Takano, T.; Deane, R.; Nedergaard, M. Sleep drives metabolite clearance from the adult brain. Science, 2013, 342(6156), 373-377.
[http://dx.doi.org/10.1126/science.1241224] [PMID: 24136970]
[186]
Kalsbeek, A.; Palm, I.F.; La Fleur, S.E.; Scheer, F.A.; Perreau-Lenz, S.; Ruiter, M.; Kreier, F.; Cailotto, C.; Buijs, R.M. SCN outputs and the hypothalamic balance of life. J. Biol. Rhythms, 2006, 21(6), 458-469.
[http://dx.doi.org/10.1177/0748730406293854] [PMID: 17107936]
[187]
Reiter, R.J.; Mayo, J.C.; Tan, D.X.; Sainz, R.M.; Alatorre-Jimenez, M.; Qin, L. Melatonin as an antioxidant: Under promises but over delivers. J. Pineal Res., 2016, 61(3), 253-278.
[http://dx.doi.org/10.1111/jpi.12360] [PMID: 27500468]
[188]
Tönnies, E.; Trushina, E. Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. J. Alzheimers Dis., 2017, 57(4), 1105-1121.
[http://dx.doi.org/10.3233/JAD-161088] [PMID: 28059794]
[189]
Wang, J.Z.; Wang, Z.F. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol. Sin., 2006, 27(1), 41-49.
[http://dx.doi.org/10.1111/j.1745-7254.2006.00260.x] [PMID: 16364209]
[190]
Zhu, L.Q.; Wang, S.H.; Ling, Z.Q.; Wang, Q.; Hu, M.Q.; Wang, J.Z. Inhibition of melatonin biosynthesis activates protein kinase a and induces Alzheimer-like tau hyperphosphorylation in rats. Chin. Med. Sci. J., 2005, 20(2), 83-87.
[PMID: 16075743]

Rights & Permissions Print Cite
Article Metrics
26
© 2024 Bentham Science Publishers | Privacy Policy